WE CLAIM,
1. A composition for treating mycobacterial infections in a subject in need thereof,
comprising:
1-3000 mg of diosmin, or diosmetin, or a pharmaceutically acceptable salt thereof; 1-1500 mg of amoxicillin; and 1-375 mg of clavulanic acid.
2. The composition of claim 1, further comprising one or more anti-mycobacterial agents selected from the group comprising of ethambutol, isoniazid, pyrazinamide, rifampicin, streptomycin, amikacin, kanamycin, capreomycin, viomycin, enviomycin, ciprofloxacin, levofloxacin, moxifloxacin, ethionamide, prothionamide, cycloserine, terizidone, clarithromycin, linezolid, thioacetazone and thioridazine.
3. The composition of claim 1, wherein the bacterial infection is selected from an infection caused by Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium marinum, Mycobacterium smegmatis, Mycobacterium bovis, Mycobacterium africanum, Mycobacterium canetti, Mycobacterium caprae, Mycobacterium microti, Mycobacterium kansasii, Mycobacterium leprae, Mycobacterium avium, Mycobacterium paratuberculosis, Mycobacterium pinnipedii, Escherichia coli, Enterococcus faecalis, Enterococcus faecium, Klebsiella pnemoniae, shigella sonnei, Salmonella enterica or Yersinia enterocolitica.
4. The composition of claim 3, wherein the mycobacterial infection is drug resistant tuberculosis.
5. The composition of claim 1, further comprising one or more beta-lactam
antibiotics selected from the group of benzylpenicillin, phenoxymethyl penicillin,

procaine penicillin, cloxacillin, dicloxacillin, flucloxacillin, methicillin, nafcillin, oxacillin, temocillin, ampicillin, mecillinam, carbenicillin, ticarcillin, azlocillin, mezlocillin, piperacillin, cefazolin, cephalexin, cephalosporin, cephalothin, cefaclor, cefamandole, cefuroxime, cefotetan, cefoxitin, cefixime, cefotaxime, cefpodoxime, ceftazidime, ceftriaxone, cefepime, cefpirome, biapenem, doripenem, ertapenem, faropenem, imipenem, meropenem, panipenem, razupenem, tebipenem, thienamycin, aztreonam, tigemonam, nocardicin, and tabtoxinine.
6. The composition of claim 1, further comprising one or more beta-lactamase inhibitors selected from the group comprising of sulbactam, tazobactam, avibactam and vaborbactam.
7. The composition of claim 1, wherein the weight ratio of amoxicillin to clavulanic acid is in the range of 2: 1 to 16: 1.
8. The composition of claim 1, wherein the weight ratio of diosmin, diosmentin, or a pharmaceutically acceptable salt thereof to amoxicillin and clavulanic acid is 2: 1 or greater.
9. An oral dosage form comprising the composition of claim 1.
10. A method of inhibiting D,D transpeptidase and L,D transpeptidase activity in
bacterial cells, comprising: adding a composition comprising: diosmin, or diosmetin, or a
pharmaceutically acceptable salt thereof; amoxicillin; and clavulanic acid, wherein
diosmin, diosmentin, or a pharmaceutically acceptable salt thereof binds to one or more
residues of L,D transpeptidase 1 (Ldtl) and L,D transpeptidase 2 (Ldt2) thereby
inhibiting L,D transpeptidase activity.